Page 8 - Health Sector

Lord's Mark Microbiotech set to launch saliva-based organ age test

The company claims this test will be priced between Rs 15,000 and 20,000, making it more affordable than the current market options, which range from Rs 30,000 to 40,000

Separate marketing code: Medical devices industry welcomes govt's move

A separate marketing practices code has been a long-standing demand for medical devices. Currently, the industry has to comply with the marketing practices code for pharmaceuticals

Indian pharma market registers over 6% growth in July '24: Pharmarack

"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report

Fortis Healthcare Q1 results: Profit rises 40% over hospital biz growth

The company's revenue from operations rose to Rs 1,859 crore in Q1FY25, a 12.2 per cent Y-o-Y rise from Rs 1,657 crore reported in Q1FY24

Kerala, Tamil Nadu see fewer hospital admissions under Ayushman Bharat

The lesser numbers in Telangana are due to the presence of the state's own health insurance scheme for the poor, 'Aarogyasri,' which later merged with AB-PMJAY only in 2021

Max Healthcare Q1 results: Net profit drops 1.6%, revenue up by 20%

Max to invest Rs 230 crore to set up 250 bed hospital in Mohali

Rare disease patients suffer as CoEs under-utilise funds, shows data

5 of 12 CoEs formed to treat rare diseases have spent less than 35% funds allotted

Eco Survey: Quadruple psychiatrists, integrate mental health in schools

Even as experts acknowledge the challenge, they also point to a rising trend in the number of psychiatrists due to an increased number of postgraduate seats in recent years

Covid-19: India lost 2.6 years' life expectancy between 2019 and 2020

The study found that the decline was more pronounced among females (3.1 years) compared to males (2.1 years)

US Biosecure Act spells long-term boost for Indian CDMO, CRO firms

As American biopharma looks to diversify sourcing, Indian companies stand to benefit

Govt should spend 2.5% of GDP on health sector, says FICCI panel chief

The Budget Session of Parliament will commence on July 22 and subject to exigencies of Government Business, the session may conclude on August 12

Culling, surveillance but no vaccine strategy to fight 'bird flu'

Experts said as India falls on the one of main pathways that migratory birds take to move between continents, its water bodies are always prone to the spread of influenza from birds

Rising focus: Budget push likely for social sector to lift rural demand

Bumper RBI dividend may help govt increase funding

From customer care to health, AI applied for practical use in daily life

Indian startups and researchers have over the years worked on the technology to build practical solutions

Centre limits self-declaration certificate for ads of food, health sectors

It also announced that the facility for uploading the certificate by advertisers/advertising agencies for TV and radio ads has been made operational on the Broadcast Seva Portal

HealthCare Global Enterprises acquires Andhra-based MGCHRI for Rs 414 cr

This move positions HCG as a leader in a highly attractive micro-market, benefiting from a high-quality primary catchment area and substantial secondary catchment from neighboring states

Budget 2024: Experts urge higher Ayushman rates, subsidised adult vaccines

Sources suggest that the government may expand the ambit of the Ayushman Bharat scheme to cover everyone over 70 years

Budget 2024: Boost for women through subsidies, health initiatives expected

During her Interim Budget 2024 speech this February, the Finance Minister had highlighted significant achievements and ongoing efforts for women empowerment

NHM helped increase central govt's spending on healthcare: CSEP-CPR study

Researchers add that this was largely due to the launch and subsequent expansion of spending on NHM in the first eight years

Cipla to invest additional 3 mn euro in mRNA technology company Ethris

The aim is to accelerate Cipla's entry into the mRNA space and deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets